CYSTADROPS

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Estonia, Finland, France, Ireland, Israel, Lithuania, Netherlands, Poland, UK.

Active ingredients

The drug CYSTADROPS contains one active pharmaceutical ingredient (API):

1	Mercaptamine UNII IF1B771SVB - CYSTEAMINE HYDROCHLORIDE
	Mercaptamine reduces corneal cystine crystal accumulation acting as a cystine-depleting agent by converting cystine to cysteine and cysteine-cysteamine mixed disulfides.
	Read more about Mercaptamine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CYSTADROPS Eye drops solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01XA21		S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals
Discover more medicines within S01XA21

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02485605
EE	Ravimiamet	1737064
FI	Lääkealan turvallisuus- ja kehittämiskeskus	382318, 564033
FR	Base de données publique des médicaments	65839815
GB	Medicines & Healthcare Products Regulatory Agency	345926
IL	מִשְׂרַד הַבְּרִיאוּת	8501
LT	Valstybinė vaistų kontrolės tarnyba	1082007, 1091272
NL	Z-Index G-Standaard, PRK	149845
PL	Rejestru Produktów Leczniczych	100387792
US	FDA, National Drug Code	55292-410